专利检索_ 作用于酯键的水解酶专利检索_ 作用于酯键的水解酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing	US14775930	2014-03-14	US10119133B2	2018-11-06	J. Keith Joung; Jeffry D. Sander; Yan-fang Fu; Morgan Maeder
CRISPR-Cas genome editing uses a guide RNA, which includes both a complementarity region, which binds the target DNA by base-pairing, and a Cas9-binding region, to direct a Cas9 nuclease to a target DNA. Further disclosed are methods for increasing specificity of RNA-guided genome editing using CRISPR/Cas9 systems by using truncated guide RNAs (tru-gRNAs).
182	Methods and compositions for targeted single-stranded cleavage and targeted integration	US15495325	2017-04-24	US10113207B2	2018-10-30	Jianbin Wang
Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
183	Engineered CRISPR-Cas9 Nucleases with Altered PAM Specificity	US15935334	2018-03-26	US20180282714A1	2018-10-04	J. Keith Joung; Benjamin Kleinstiver
Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
184	METHODS, COMPOSITIONS, AND DEVICES FOR SUPPLYING DIETARY FATTY ACID NEEDS	US16000327	2018-06-05	US20180280249A1	2018-10-04	Alexey L. Margolin; Robert Gallotto; Bhami Shenoy
Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
185	Chimeric Proteins and Methods of Regulating Gene Expression	US15806756	2017-11-08	US20180273980A1	2018-09-27	Lei S. Qi; P.C. Dave P. Dingal
The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.
186	Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation	US15303971	2015-04-14	US10071077B2	2018-09-11	Jan Beute
The invention involves the use of compounds from the class of aroyl-2H-imidazol-2-ones such as enoximone or a pharmaceutically acceptable salt thereof for modulating the immune system involved in a topic and immune-related disorders. In particular, the invention involves the use of (1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-on) or a pharmaceutically acceptable salt thereof. The invention also involves a pharmaceutical composition including aroyl-2H-imidazol-2-on or a pharmaceutically acceptable salt thereof in an active quantity for the treatment of a topic and immune-related disorders, by modulating the immune system involved in a topic and immune-related disorders. Preference is especially given to a pharmaceutical composition in a dosage unit of 5, 10 or 20 mg, based on the quantity of the active ingredient.
187	METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM	US15891496	2018-02-08	US20180237798A1	2018-08-23	Philippe DUCHATEAU; Andre CHOULIKA; Laurent POIROT
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
188	Rationally-designed single-chain meganucleases with non-palindromic recognition sequences	US15132941	2016-04-19	US10041053B2	2018-08-07	James Jefferson Smith; Derek Jantz
Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
189	Methods and compositions for nuclease design	US14731821	2015-06-05	US09970001B2	2018-05-15	Jeffrey C. Miller
Methods and compositions for genetic alteration of cells are provided.
190	FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks	US14019244	2013-09-05	US09963711B2	2018-05-08	Noel Cogan; John Forster; Matthew Hayden; Tim Sawbridge; German Spangenberg; Steven R. Webb; Manju Gupta; William Michael Ainley; Matthew J. Henry; Jeffrey C. Miller; Dmitry Y. Guschin
A method of gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a cell, to generate a break in the FAD2 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.
191	Nuclease-mediated regulation of gene expression	US15172626	2016-06-03	US09957501B2	2018-05-01	Andreas Reik; John A. Stamatoyannopoulos; Jeff Vierstra
The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
192	METHODS OF SPECIFICALLY LABELING NUCLEIC ACIDS USING CRISPR/CAS	US15787319	2017-10-18	US20180105867A1	2018-04-19	Ming Xiao; Harold C. Riethman; Wenhui Hu; Jennifer McCaffrey
Provided herein are methods of detecting a target nucleic acid sequence. In one embodiment, the method includes contacting genomic DNA with a guide RNA having a portion complementary to the target sequence in the genomic DNA and with Cas9 nickase to produce a single-strand break in the genomic DNA at a specific location adjacent to the target sequence. The method further includes contacting the nicked DNA with a polymerase and fluorescently labeled nucleotide. The fluorescently labeled nucleotide is incorporated into the nicked DNA at the specific location and the target nucleic acid sequence is detected via fluorescent label.
193	Engineered CRISPR-Cas9 nucleases with altered PAM specificity	US15060424	2016-03-03	US09944912B2	2018-04-17	J. Keith Joung; Benjamin Kleinstiver
Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
194	USE OF ENZYMES WITH A WIDE PH ACTIVITY RANGE AS MEDICAMENTS FOR PROMOTING DIGESTION	US15545583	2016-01-22	US20180073001A1	2018-03-15	Marcus Wolf William Hartmann; Ingo Aldag
Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.
195	Compositions and methods comprising sequences having meganuclease activity	US15289993	2016-10-11	US09909110B2	2018-03-06	Ericka Bermudez; Andrew Mark Cigan; James English; Saverio Carl Falco; Huirong Gao; Lu Liu; Zhan-Bin Liu; Azalea Ong; Sergei Svitashev; Joshua K Young
Compositions and methods comprising polynucleotides and polypeptides having meganuclease activity are provided. Further provided are nucleic acid constructs, yeast, plants, plant cells, explants, seeds and grain having the meganuclease sequences. Various methods of employing the meganuclease sequences are provided. Such methods include, for example, methods for producing a meganuclease with increased activity at a wide range of temperatures, methods for producing a yeast, plant, plant cell, explant or seed comprising a meganuclease with increased activity.
196	Stabilized RNA solutions	US15063139	2016-03-07	US09896682B2	2018-02-20	Xiao-Song Gong; Cindy Wan
Methods and compositions are described herein for protecting RNA from autocatalytic and divalent cation induced degradation in an aqueous solution.
197	Pectin extraction from coffee pulp	US14647569	2013-11-27	US09896572B2	2018-02-20	Andres Felipe Belalcazar Otalora
The invention provides a coffee pulp treatment process comprising (a) Providing coffee pulp, obtainable from a production process for producing green coffee beans from coffee cherries; (b) extracting from the coffee pulp a pectin comprising extract, wherein extraction is performed under acid conditions or alkaline conditions, to provide the pectin comprising extract; (c) enzymatic treatment of the pectin comprising extract, wherein the enzymatic treatment comprises a treatment with one or more enzymes selected from the group consisting of an esterase and a reductase, to provide a enzymatically treated pectin material; and (d) extraction of polyphenol functionalized coffee pectin extract from the enzymatically treated pectin material.
198	METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION	US15502720	2015-09-01	US20180044700A1	2018-02-15	Jennifer A. DOUDNA; Steven LIN; Brett T. STAAHL
The present disclosure provides compositions and methods of site-specific modification of a target DNA, or a protein associated with a target DNA, in a eukaryotic cell. The present disclosure provides methods of binding a target DNA in a eukaryotic cell.
199	Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor	US14898248	2014-06-19	US09890369B2	2018-02-13	Christopher H. Bachran; Stephen H. Leppla
Disclosed is a protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a Bacillus anthracis toxin lethal factor (LF) or a functional portion of LF. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed.
200	Sympathetic printed-matter and method of producing the same	US15223490	2016-07-29	US09868874B2	2018-01-16	Myoung Ku Lee; Jeong Yong Ryu; Chang Geun Kim; Kwang Seob Lee; Jae Hoon Lee; Han Je Cho; Hyeok Jun Kwon; David Guerin; Philippe Martinez
Using the sympathetic printed-matter according to the present invention, a hidden content can be visualized just by wetting. Therefore, it is possible to remove necessities of the sympathetic ink and a special material such as reagent or equipment for visualizing hidden contents. In addition, since the hidden contents disappear by removing water from the sympathetic printed-matter, the sympathetic printed-matter can be used repeatedly. Using the reading confirmation portion, whether or not the sympathetic printed-matter has been read by any other person can be easily determined. In the sympathetic printing method according to the present invention, a hydrophobic substrate can be formed using an existing gas grafting facility, and an ester hydrolase composition and the reading confirmation portion can be formed using an existing printing method. Therefore, a large amount of sympathetic printed-matters can be produced inexpensively and efficiently.

5 6 7 8 9 10 11 12 13 14

该功能需要专业版企业版VIP权限，您可以：